Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma

NCT00816634 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

94

Enrollment

OTHER

Sponsor class

Conditions

First Line Chemotherapy
Capecitabine Plus Cisplatin Versus Capecitabine Plus Paclitaxel
Advanced or Recurrent Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)

Sponsor

Samsung Medical Center